Oracle Corp (NYSE: ORCL, ETR: ORC) is further developing its ability to organize new AI (AI) capabilities, from patient portals and payer provider tools to supply chain systems and clinical trial platforms. The move highlights how large-scale technologies are accelerating their industry presence, betting that AI can solve years of inefficiency in how care is delivered and managed.
What Oracle revealed
The company disclosed various updates in September 2025, indicating that healthcare is at the heart of its enterprise growth strategy. Generation AI is at the core and is used to automate routine processes, personalize patient engagement, and enhance clinical research.
Upgrading the Patient Experience – Oracle brings new AI capabilities to the Patient Portal. These include conversation and prediction tools for scheduling appointments, billing, and navigating medical records. Goal: Reduce management load and improve ease of use for patients and clinicians.
Payer-Provider Collaboration – Oracle has deployed a feature aimed at speeding up billing processing and resolving conflicts between payer and provider data. These are long-standing friction points in US healthcare, and Oracle places AI as a way to reduce delays, errors and costs.
Supply Chain and Operations – The company is applying for AI to streamline the supply chain of hospitals, forecast demand, and identify potential shortages. Given the global turmoil of recent years, these predictive analytics tools aim to improve the resilience of organizations relying on complex logistics.
Clinical Trials and Drug Discovery Discovery – Oracle is enhancing its Electronic Data Capture (EDC) solutions to streamline data collection and monitoring in trials. Additionally, partnerships such as ABSCI and AMD aim to speed up drug discovery workflows. Oracle's cloud infrastructure and AI tools are designed to reduce market time and costs for biotech companies and Pharma.
These announcements are built on Oracle's 2022 acquisition of Cerner, which reflects its strategy of strengthening its healthcare presence and embedding AI into the infrastructure of healthcare delivery. However, there is still a recruitment risk. Regulatory oversight, workflow integration, clinician acceptance, and demonstrable return on investment are all hurdles.
What does this mean for the industry?
Oracle's Push demonstrates the great technology that deals with healthcare not only as vertical for healthcare, but also as a domain of AI-driven transformation across operations, patient engagement, clinical research and supply chains. For providers, payers, and life sciences companies, this means more competition, more choices, and higher expectations for software partners. For investors, these moves highlight that Oracle is doubling AI as a growth lever for its healthcare business.
ASX companies to watch
In Australia, several listed companies operate in related spaces, demonstrating how Oracle's global movement intersects local innovation and investment opportunities.
Among them, Pathkey.ai Ltd (ASX:PKY) is gaining attention with its TrialKey platform, which applies machine learning to predict the probability of successful clinical trials. The first real-world examination of the year gave forecasts in line with about 73% of results across 11 programs, providing potentially valuable tools for biotech sponsors, insurance companies and even investors.
Read more: pathkey.ai validates TrialKey predictions in a strong alignment with clinical outcomes
On the hardware side, BrainChip Holdings Ltd (ASX:BRN) pursues neural AI for low power processing at the edges that could potentially use applications for medical devices. Infrastructure players are also associated with the broader AI demand context. Data center operator NextDC (ASX:NXT) is gaining demand from AI workloads that support tools like Oracle, but connectivity expert MegaPort Ltd (ASX:MP1) helps you need quick and flexible networks.
Most are in different stages of commercial maturity, but it shows how Healthcare's AI advancements are reflected in activities across the Australian technology environment, from predictive testing analysis to the infrastructure and components that enable these systems.
Get stock
Oracle's recent announcements show that AI is at the heart of healthcare enterprise software, not just incremental enhancements.
The company's current challenges are the challenges. These tools are delivered in a real clinical setting, overcome regulatory and data privacy hurdles, and make AI adoption seamless for users. For local businesses, opportunities are to differentiate through specialization, speed, understanding of regulatory, and partnerships.
